Intuitive Surgical, Inc. (NASDAQ:ISRG) Stock Holdings Trimmed by Cim LLC

Cim LLC decreased its position in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 2.5% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 30,577 shares of the medical equipment provider's stock after selling 789 shares during the period. Intuitive Surgical comprises approximately 2.3% of Cim LLC's portfolio, making the stock its 19th biggest holding. Cim LLC's holdings in Intuitive Surgical were worth $15,960,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the company. Onefund LLC grew its stake in Intuitive Surgical by 1.9% in the 4th quarter. Onefund LLC now owns 947 shares of the medical equipment provider's stock worth $494,000 after acquiring an additional 18 shares during the period. AlphaCore Capital LLC lifted its stake in shares of Intuitive Surgical by 4.2% during the 4th quarter. AlphaCore Capital LLC now owns 451 shares of the medical equipment provider's stock worth $235,000 after purchasing an additional 18 shares during the period. Journey Strategic Wealth LLC boosted its holdings in shares of Intuitive Surgical by 1.9% during the fourth quarter. Journey Strategic Wealth LLC now owns 1,039 shares of the medical equipment provider's stock worth $542,000 after purchasing an additional 19 shares during the last quarter. FSM Wealth Advisors LLC grew its position in shares of Intuitive Surgical by 3.7% in the fourth quarter. FSM Wealth Advisors LLC now owns 526 shares of the medical equipment provider's stock valued at $275,000 after purchasing an additional 19 shares during the period. Finally, Parkside Financial Bank & Trust increased its stake in Intuitive Surgical by 2.6% in the fourth quarter. Parkside Financial Bank & Trust now owns 747 shares of the medical equipment provider's stock valued at $390,000 after purchasing an additional 19 shares during the last quarter. Hedge funds and other institutional investors own 83.64% of the company's stock.

Wall Street Analyst Weigh In

ISRG has been the topic of a number of research analyst reports. Evercore ISI decreased their price target on Intuitive Surgical from $510.00 to $470.00 and set an "in-line" rating on the stock in a research note on Wednesday, April 23rd. Erste Group Bank cut shares of Intuitive Surgical from a "strong-buy" rating to a "hold" rating in a research report on Monday, March 17th. Citigroup reaffirmed a "buy" rating and set a $650.00 price target (up previously from $590.00) on shares of Intuitive Surgical in a research report on Thursday, May 22nd. Royal Bank of Canada cut their price target on shares of Intuitive Surgical from $630.00 to $605.00 and set an "outperform" rating on the stock in a research note on Wednesday, April 23rd. Finally, Barclays lowered their price objective on shares of Intuitive Surgical from $684.00 to $635.00 and set an "overweight" rating for the company in a research note on Thursday, April 24th. Five analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $596.05.

Intuitive Surgical Stock Down 0.8%

Shares of NASDAQ ISRG traded down $4.61 on Friday, hitting $551.14. The company had a trading volume of 2,090,952 shares, compared to its average volume of 1,647,940. Intuitive Surgical, Inc. has a 12-month low of $396.48 and a 12-month high of $616.00. The firm has a market capitalization of $197.54 billion, a P/E ratio of 85.98, a PEG ratio of 5.85 and a beta of 1.70. The business has a 50 day moving average of $515.81 and a two-hundred day moving average of $538.43.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last released its quarterly earnings results on Tuesday, April 22nd. The medical equipment provider reported $1.81 earnings per share for the quarter, topping analysts' consensus estimates of $1.71 by $0.10. The firm had revenue of $2.25 billion during the quarter, compared to analysts' expectations of $2.19 billion. Intuitive Surgical had a return on equity of 14.55% and a net margin of 27.81%. During the same quarter in the prior year, the business earned $1.50 EPS. On average, sell-side analysts anticipate that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current year.

Insider Activity

In other Intuitive Surgical news, EVP Brian Edward Miller sold 8,900 shares of the firm's stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $485.07, for a total transaction of $4,317,123.00. Following the completion of the sale, the executive vice president now owns 5,758 shares in the company, valued at $2,793,033.06. This trade represents a 60.72% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Robert Desantis sold 188 shares of the company's stock in a transaction that occurred on Monday, April 28th. The shares were sold at an average price of $515.91, for a total value of $96,991.08. Following the completion of the transaction, the executive vice president now directly owns 5,224 shares in the company, valued at approximately $2,695,113.84. The trade was a 3.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 30,111 shares of company stock worth $15,364,055. 0.70% of the stock is currently owned by company insiders.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.